Diagnostic Issues in Thrombophilia: A Laboratory Scientist's View

ABSTRACT

Thrombophilia can be defined as an increased tendency to thrombosis. There are several defined risk factors for thrombosis, and these are generally separated into acquired and congenital factors. Congenital risk factors include deficiencies or defects in natural anticoagulants, such as antithrombin, protein C and protein S, and genetic polymorphisms such as prothrombin G20210A and the cleavage-resistant factor mutation, factor V Leiden, which leads to a condition known as activated protein C resistance. Acquired risk factors include antiphospholipid antibodies, detected as lupus anticoagulants, and/or anticardiolipin or anti-β₂-glycoprotein I antibodies. Elevated homocysteine, immobility, increasing age, surgery, cancer, poor nutrition, pregnancy, high levels of clotting factors, and use of oral contraceptives and hormone replacement therapy comprise other risk factors. Each of these constitutes an element of increased risk, which is compounded when concomitant. There is ongoing debate regarding relative and compound risks, the value of laboratory screening, whom to screen for with these markers, and the form and duration of clinical management. This report briefly explores, from a scientist's perspective, some important issues that are sometimes overlooked.

Thrombophilia - laboratory testing - protein C - protein S - antithrombin - activated protein C resistance - lupus anticoagulant - antiphospholipid antibodies

REFERENCES

• 1 Mannucci P M. Laboratory detection of inherited thrombophilia: a historical perspective.  Semin Thromb Hemost. 2005;  31 5-10
• 2 Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia.  Semin Thromb Hemost. 2005;  31 25-32
• 3 Hertzberg M. Genetic testing for thrombophilia mutations.  Semin Thromb Hemost. 2005;  31 33-38
• 4 Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests.  Semin Thromb Hemost. 2005;  31 17-24
• 5 Falanga A. Thrombophilia in cancer.  Semin Thromb Hemost. 2005;  31 104-110
• 6 Allman-Farinelli M, Dawson B. Diet and aging: bearing on thrombosis and hemostasis.  Semin Thromb Hemost. 2005;  31 111-117
• 7 Gallus A. Travel, venous thromboembolism, and thrombophilia.  Semin Thromb Hemost. 2005;  31 90-96
• 8 Hoffman R, Brenner B. Thrombophilia-related issues in women and children.  Semin Thromb Hemost. 2005;  31 97-103
• 9 Bucek R A, Reiter M, Quehenberger P, Weltermann A, Kyrle P A, Minar E. Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?.  Br J Haematol. 2003;  120 123-128
• 10 Gallus A. Management options for thrombophilias.  Semin Thromb Hemost. 2005;  31 118-126
• 11 Martinelli I. Pros and cons of thrombophilia testing: pros.  J Thromb Haemost. 2003;  1 410-411
• 12 Machin S J. Pros and cons of thrombophilia testing: cons.  J Thromb Haemost. 2003;  1 412-413
• 13 Martinelli I. Rebuttal to: pros and cons of thrombophilia testing: pros.  J Thromb Haemost. 2003;  1 1311-1312
• 14 Lane D A, Mannucci P M, Bauer K A et al.. Inherited thrombophilia: part 2.  Thromb Haemost. 1996;  76 824-834
• 15 Walker I D, Greaves M, Preston F E. On behalf of the Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guideline: investigation and management of heritable thrombophilia.  Br J Haematol. 2001;  114 512-528
• 16 Van Cott E M, Laposata M, Prins M H. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: venous thromboembolism, myocardial infarction, stroke, and other conditions.  Arch Pathol Lab Med. 2002;  126 1281-1295
• 17 De Stefan V, Ross E, Paciaron K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications.  Haematologica. 2002;  87 1095-1108
• 18 Favaloro E J, Bonar B, Sioufi J et al.. On behalf of the RCPA QAP in Haematology. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Haematology Quality Assurance Program.  Semin Thromb Hemost. 2005;  31 49-58
• 19 Meijer P, Haverkate F. External quality assessment and the laboratory diagnosis of thrombophilia.  Semin Thromb Hemost. 2005;  31 59-65
• 20 Jennings I, Kitchen S, Woods TAL, Preston F E. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assurance Service (blood coagulation) quality assurance program.  Semin Thromb Hemost. 2005;  31 66-72
• 21 Hertzberg M, McDonald D, Neville S, Favaloro E J. Multi-laboratory testing and detection of genetic mutations in congenital thrombophilia.  Am J Clin Pathol. 2005;  , (in press)
• 22 Favaloro E J, Wong R CW, Silvestrini R, McEvoy R, Jovanovich R, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody and beta₂-glycoprotein I antibody testing.  Semin Thromb Hemost. 2005;  31 73-84
• 23 Favaloro E J. Learning from the peer-assessment external quality assurance multi-laboratory thrombophilia test process.  Semin Thromb Hemost. 2005;  31 85-89
• 24 Preston F E, Kitchen S, Jennings I, Woods T A. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia.  Thromb Haemost. 1999;  82 1556-1557
• 25 Lutz C T, Foster P A, Noll W W et al.. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.  Clin Chem. 1998;  44 1356-1358
• 26 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-a cause for concern.  Thromb Haemost. 2002;  88 690-691
• 27 Favaloro E J, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.  Pathology. 2002;  34 348-355
• 28 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101 1827-1832
• 29 Wong R C, Adelstein S, Gillis D, Favaloro E J. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.  Semin Thromb Hemost. 2005;  31 39-48